PMN ProMIS Neurosciences

$PMN bold statement to hire CCO from big competitor like $BIIB and $RHHBY to a small Phase 1b Company Dr. Ivana Rubino must have huge positive faith for the data readout in January 27? She saw more and knows more than all other how to proceed and make PMN310 Precise AD a success! Good luck we are on the right path!

$PMN I said they will bring it down but they didn’t know that I’ll load up to 5 digits shares in between! I am prepared for another shares of 5 digits

$PMN Wow Neil Warma CEO of ProMIS was so full of enthusiasm and power in his presentation at Moody he has something big to tell very soon imo

$PMN short interest decreased substantially in last reporting period. very poor risk/reward for shorts, $100 of upside, $5 of downside. only and similar low-knowledge retail shorts remain and thats not good company to be in.

$PMN its ‘endure’ and with spelling like that you might need PMN 310 one day Toe. DW i’m going to take you out for a drink with my millions after ph 1b hits. how did you like the bullish reversal yesterday Toe?

$PMN “Neuroscience has been at the center of my career, and I have had the privilege of working across several areas in which major scientific advances have transformed what is possible for patients,” said Dr. Rubino. “Alzheimer’s disease is perhaps one of the clearest examples: although we have made significant progress, meaningful scientific, clinical and access challenges remain. What attracted me to ProMIS was both the differentiated science behind PMN310 and the broader potential of the company’s approach to targeting toxic misfolded proteins. If the clinical data in the ongoing Alzheimer’s trial continue to be supportive, PMN310 could represent an important next step in Alzheimer’s treatment. I am excited to help translate the science into development and commercial strategies that can ultimately create meaningful value for patients, families and the neuroscience community.” Awesome

$PMN Come on. Safest anti-amyloid out there (zero ARIA) and trending downward towards $ABOS readout? With a cash runway through 2027 and warrants to be exercised after the likely positive ph1b? Based on approved AD treatment I expect it will work. Main remaining risk is that the selective mabs against the toxic oligomers dont work

$PMN yes one person has brain swelling and that's toejoe, oh pardon me he does not because you would have to have a brain in order for it to swell. Clinical trials are going well and I wish they had an antibody for big mouth disease, toejoe would be a perfect patient.

$PMN sentiment was like sub 40 wasn't it? how did it turn to 71 - no idea how stocktwits measures this and how accurate this is fits what is going on though with the conferences , timelines and possibilites 👍

$PMN Perhaps Biogen is planning a buyout of Promis? They have about a billion and a half in loose change kicking around; they may need a partner! Things are really looking good: "During her time at Biogen and F. Hoffmann-La Roche, Dr. Rubino led and helped shape Alzheimer’s disease programs across late-stage development, scientific and medical strategy, market preparation and commercialization planning. Her experience includes global leadership supporting the LEQEMBI® franchise, preparation for next-generation Alzheimer’s therapies, and the build-out of large global medical organizations across the United States, Europe and other major markets. She also held senior global leadership roles across multiple sclerosis, spinal muscular atrophy and neuropsychiatry." Promis' PMN310, for all intents and purposes, seems to be superior to the 2 leading drugs, (Leqembi & Kisunla)! Wow!!

$PMN AI overview: • Late 2024 to Late 2026 — Phase 1b 12-Month Treatment Completion: Dosing for all patients in the 12-month trial is on track to conclude by the end of 2026. • Q1 2027 — Unblinded Phase 1b Top-line Data Readout: This represents the single largest catalyst for the program. The unblinded 12-month package is expected to deliver definitive safety profiles, a broad biomarker package, and—for the first time—preliminary cognitive outcome measures. • 2027 — FDA Alignment & Potential Phase 3 Path: Following compilation of the full Phase 1b dataset, the company plans to utilize its Fast Track status to hold an official FDA meeting. If the top-line results are favorable, ProMIS aims to advance PMN310 directly into a single registration/Phase 3 study. • Subcutaneous Formulation Development: In parallel with clinical progression, the company is continuing to advance a subcutaneous version of PMN310 paired with an auto-injector device for more convenient patient administration.